However, after decades of stagnation, recent advances in immunotherapy with immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen-activated protein kinase kinase) inhibitors have considerably improved the prognosis of metastatic melanoma. This evidence concerns the gene BRAF and metastatic melanoma.